|
The yet2.com global technology marketplace lists intellectual property, technology, and patents for technology transfer, technology licensing, patent licensing and patent sale. As premier technology brokers, yet2.com offers this essential IP marketplace for technology owners, technology seekers, and technology brokers interested in technology acquisition, patent licensing, intellectual property licensing (IP licensing), and intellectual property transfer.
more...
|
| This is an abstract of a technology that is available for sale or license. yet2.com can introduce you confidentially to the owner of this technology. |
| To view the complete TechPak, please register with us. |
 |
| Enter a keyword or phrase below, and search now to find other technologies of interest. |
|
|
|
|
 |
| The present invention relates to methods for screening cancer patients for susceptibility to a particular treatment protocol and to a method of treatment of those patients found positive in the screen. Loss or inactivation of tumor suppressor genes is among the genetic defects which participate in the multi-step process that causes cancer. Some of the tumor suppressor genes are part of the genetic machinery which controls apoptosis and therefore their deregulation may lead to tumor growth. One of the tumor suppressor genes which is shut off in various cancer cells is DAP-kinase where the lack of DAP-kinase expression is caused by hypermethylation of the gene. In animal models DAP-kinase expression can be restored by treatment of cells with 5-aza-2'-deoxycytidine, a drug which inhibits DNA methylation. This suppresses the ability of the cells to form lung metastases. This invention is relevant to diagnosis in identifying cancer patients whose tumor cells have a hypermethylated DAP-kinase gene and therefore are susceptible for treatment with demethylating agents. In addition, it may also be useful as a therapeutic method of preventing or limiting the spread of metastases by treatment of a patient identified with hypermethylated DAP-kinase with a therapeutically effective amount of a demethylating agent.Loss inactivation tumor suppressor genes genetic defects participate multi-step causes cancer machinery controls apoptosis deregulation severely disrupts normal tissue homeostasis terminating growth Various types epigenetic deregulations inactivate DNA deletions mutations translocations chromosomal losses methylations |
|
|
 |
|
Interested? This is an abstract of a technology that is available for sale or license. yet2.com can introduce you confidentially to the owner of this technology.
|
|
To view the complete TechPak, please register with us.
|
|
|
|
